# Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

> **NCT01251354** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 6 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** BN83495

## Key facts

- **NCT ID:** NCT01251354
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-07
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251354, "Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01251354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*